Skip to content
10-K

Annual Report

Bristol-Myers Squibb Company BMY CELG-RI

0000014272-25-000039

← back to feed
Filed
Feb 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 6, 2025 2.03B sh
Long Term Debt FY 2024 · Dec 31, 2023 $36.65B
Short Term Debt FY 2024 · Dec 31, 2023 $3.12B
Cash And Equivalents FY 2024 · Dec 31, 2023 $11.46B
Stockholders Equity FY 2024 · Dec 31, 2023 $29.43B
Current Liabilities FY 2024 · Dec 31, 2023 $22.26B
Total Liabilities FY 2024 · Dec 31, 2023 $65.67B
Current Assets FY 2024 · Dec 31, 2023 $31.77B
Total Assets FY 2024 · Dec 31, 2023 $95.16B
Shares Diluted FY 2024 · Dec 31, 2022 2.15B sh
Stock Repurchased FY 2024 · Dec 31, 2022 $8B
Dividends Paid FY 2024 · Dec 31, 2022 $4.63B
Capex FY 2024 · Dec 31, 2022 $1.12B
Operating Cash Flow FY 2024 · Dec 31, 2022 $13.07B
Eps Diluted FY 2024 · Dec 31, 2022 $2.95
Eps Basic FY 2024 · Dec 31, 2022 $2.97
Sga Expense FY 2024 · Dec 31, 2022 $7.81B
Rd Expense FY 2024 · Dec 31, 2022 $9.51B
Net Income FY 2024 · Dec 31, 2022 $6.33B
Cost Of Revenue FY 2024 · Dec 31, 2022 $10.14B
Revenue FY 2024 · Dec 31, 2022 $46.16B